Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes
Jessica R Castle, Julia M Engle, Joseph El Youssef, Ryan G Massoud, Kevin C J Yuen, Ryland Kagan, W Kenneth Ward, Jessica R Castle, Julia M Engle, Joseph El Youssef, Ryan G Massoud, Kevin C J Yuen, Ryland Kagan, W Kenneth Ward
Abstract
Objective: To minimize hypoglycemia in subjects with type 1 diabetes by automated glucagon delivery in a closed-loop insulin delivery system.
Research design and methods: Adult subjects with type 1 diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain parameters, and six subjects received glucagon in a more prolonged manner using low-gain parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infusions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin after meal announcement.
Results: Automated glucagon plus insulin delivery, compared with placebo plus insulin, significantly reduced time spent in the hypoglycemic range (15 +/- 6 vs. 40 +/- 10 min/day, P = 0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypoglycemic events (1.0 +/- 0.6 vs. 2.1 +/- 0.6 events/day, P = 0.01) and the need for carbohydrate treatment (1.4 +/- 0.8 vs. 4.0 +/- 1.4 treatments/day, P = 0.01). Glucagon given with low-gain parameters did not significantly reduce hypoglycemic event frequency (P = NS) but did reduce frequency of carbohydrate treatment (P = 0.05).
Conclusions: During closed-loop treatment in subjects with type 1 diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic control.
Figures
References
- Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 2003;26:1902–1912
- Cryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937–948
- Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF: Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344–3350
- El Youssef JE, Castle J, Ward WK: A review of closed-loop algorithms for glycemic control in the treatment of type 1 diabetes. Algorithms 2009;2:518–532
- Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R: Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers J Pharm Sci 1999;88:991–995
- Hartley M, Thomsett MJ, Cotterill AM: Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006;42:108–111
- Haymond MW, Schreiner B: Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001;24:643–645
- Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H: Wearable artificial endocrine pancrease with needle-type glucose sensor. Lancet 1982;2:1129–1131
- Ward WK, Engle J, Duman HM, Bergstrom CP, Sonia FK, Federiuk IF: The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors J 2008;8:89–96
- El-Khatib FH, Jiang J, Damiano ER: Adaptive closed-loop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic Swine. J Diabetes Sci Technol 2007;1:181–192
- Gopakumaran B, Duman HM, Overholser DP, Federiuk IF, Quinn MJ, Wood MD, Ward WK: A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional-derivative method. Artif Organs 2005;29:599–607
- Holmes G, Galitz L, Hu P, Lyness W: Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005;60:469–476
- Food and Agriculture Organization. Carbohydrates in human nutrition, Food and Agriculture Organization [article online], 1998. Available from . Accessed 15 April 2010
- Clinical and Laboratory Standards Institute. Performance metrics for continuous interstitial glucose monitoring: approved guideline, Clinical and Laboratory Standards Institute [article online], 2008. Available from . Accessed 15 April 2010
- Bolli G, De Feo P, Perriello G, De Cosmo S, Compagnucci P, Santeusanio F, Brunetti P, Unger RH: Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man: role of the beta cell and arterial hyperinsulinemia J Clin Invest 1984;73:917–922
- Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE: The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol 2006;355:501–523
- De Jong KL, Incledon B, Yip CM, DeFelippis MR: Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. Biophys J 2006;91:1905–1914
- El-Khatib FH, Jiang J, Gerrity RG, Damiano ER: Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic Swine model in vivo. Diabetes Technol Ther 2007;9:135–144
- Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T: Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res 2004;21:1274–1283
- Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F: Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007;63:599–601
- Matilainen L, Maunu SL, Pajander J, Auriola S, Jaaskelainen I, Larsen KL, Jarvinen T, Jarho P: The stability and dissolution properties of solid glucagon/gamma-cyclodextrin powder. Eur J Pharmacol Sci 2009;36:412–420
Source: PubMed